Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 9, Number 9—September 2003

Ehrlichia chaffeensis Infections among HIV-infected Patients in Human Monocytic Ehrlichiosis–Endemic Area

Thomas R. Talbot*Comments to Author , James A. Comer†, and Karen C. Bloch*
Author affiliations: *Vanderbilt University School of Medicine, Nashville, Tennessee, USA; †Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Main Article


Baseline characteristics of study cohort of HIV-positive persons residing in Tennesseea

Characteristic N (% or range)
Age (mean, y)
38.8 (21–75)

107 (80.5%)
26 (19.5%)
Baseline CD4 count (median, cells/mm3)
370 (6–1,200)
Baseline viral load (median, copies/dL)
1,003 (<400–>750,000)
On prophylaxis

122 (91.7%)
OI prophylaxis
70 (52.6%)
PCP prophylaxisb
66 (49.6%)
MAC prophylaxisc
31 (23.3%)
Average number of clinic visitsd
4.75 (1–13)
Treated with antibiotic therapyd,e
40/133 (30.1%)
Treated with doxycyclined
14/133 (10.5%)
Hospitalizedd 7/133 (5.3%)

          aHAART, highly active antiretroviral therapy; OI, opportunistic infection; PCP, Pneumocystis carinii pneumonia; MAC, Mycobacterium avium complex.
          bPCP prophylaxis: use of trimethoprim-sulfamethoxazole, dapsone, or aerosolized pentamidine therapy.
          cMAC prophylaxis: use of azithromycin or clarithromycin therapy.
          dDuring the study period.
          eAntibiotics used to treat the ongoing clinical symptoms; persons taking antibiotic therapy specifically for OI prophylaxis alone were not included.

Main Article

Page created: January 03, 2011
Page updated: January 03, 2011
Page reviewed: January 03, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.